Malaria

540 Users are discussing this topic

PatientPlus articles are written by UK doctors and are based on research evidence, UK and European Guidelines. They are designed for health professionals to use, so you may find the language more technical than the condition leaflets.

See also: Malaria written for patients
This is a notifiable disease in the UK. See the Notifiable Diseases article for more detail.

Malaria has been recognised as a human disease for thousands of years and remains one of the most common diseases affecting humans worldwide. Its impact falls almost entirely on developing countries, with the heaviest toll in Africa. Over half the world's population is thought to be exposed to the risk of contracting malaria.[1] As well as its direct health cost, it carries a significant economic burden in countries where there is endemic disease:[2] 

  • Malaria slows economic growth in Africa, fuelling the vicious cycle which perpetuates poverty.[3]
  • In Africa, it accounts for 40% of public health expenditure and 7% of the household income.[2][4] 
  • Malaria deters investment, tourism and labour-intensive cash-crops.

During the 1960s and 1970s, there was optimism that malaria could be eradicated. The 1980s and 1990s saw serious setbacks, such as the development of resistance to commonly used drugs and insecticides as well as the breakdown of control programmes and local primary health services, often in the context of regional political and economic collapse. Child deaths due to malaria doubled in sub-Saharan Africa in the 1990s and malaria re-emerged in Central Asia, Eastern Europe and previously clear areas of Southeast Asia.

After a difficult period of economic recession in the late 2000s, political will to tackle malaria picked up in recent years, culminating in the redevelopment of the Roll Back Malaria Partnership (RBMP), a global partnership of countries committed to the eradication of malaria. To this end, the RBMP recently published Action and Investment to defeat Malaria 2016-2030 (AIM) - for a malaria-free world.[5] This compliments the WHO Global Technical Strategy for Malaria 2016-2030.[6] 

Consider malaria in every febrile patient returning from a malaria-endemic area within the last year, especially in the previous three months, regardless of whether they have taken chemoprophylaxis, as prompt recognition and appropriate treatment will improve prognosis and prevent deaths.

Malaria is a parasitic disease caused by infection by species of the genus Plasmodium.

 Clinical featuresUK cases 2014
Plasmodium falciparumResponsible for severe disease and malaria-related deaths.
Incubation 7-14 days (up to one year if semi-immune); most travellers present within eight weeks.
Classical tertian and subtertian periodicity (paroxysms at 48- and 36-hour intervals) are rare; daily (quotidian) or irregular are more common.
1169 
Plasmodium vivaxCauses benign tertian malaria - fever every third day.
Incubation period of 12-17 days.
Relapse due to dormant parasites in the liver.
225
Plasmodium ovaleRelapsing course as with P. vivax.
Incubation period of 15-18 days.
130
Plasmodium malariaeCauses benign quartan malaria - fever every fourth day - but this is frequently not observed, particularly in early infection.
Long incubation period (18-40 days).
Parasites can remain dormant in the blood. 5-10% present over a year after infection. With chronic infection, can cause nephrotic syndrome.
41

A fifth species causing malaria in humans, Plasmodium knowlesi, has recently emerged. It is distributed across Southeast Asia and is often misdiagnosed by microscopy as P. malariae. However, it is potentially more serious, causing severe malaria with a rate of 6-9% and with a case fatality rate of 3%.[8]

Humans acquire malaria after being bitten by an infected mosquito. The sporozoites in the saliva of the mosquito then travel via the bloodstream to the liver where they mature or, in certain species, may lie dormant (when they are known as hypnozoites). The mature organisms then rupture to release further organisms (merozoites) into the blood, where they invade red blood cells and undergo asexual reproduction. Feeding mosquitoes ingest these in a blood meal and in the mosquito gut they undergo sexual reproduction to produce thousands of infective sporozoites, and the cycle continues.

Malaria occurs almost exclusively in the tropics and subtropics. About 3.2 billion people - nearly half of the world's population - are at risk of malaria. In 2015, there were approximately 214 million cases and roughly 438,000 malaria deaths. Whilst this figure is high, mortality rate has decreased by 60% since 2000 due to increased global prevention and control measures. Sub-Saharan Africa still carries the brunt of the global malaria burden. In 2015, 89% of malaria cases and 91% of malaria deaths occurred in the region.[9] 

Risk factors

The groups most at risk of developing severe disease are:[10] 

  • The poor (60% of deaths from malaria worldwide occur in the poorest 20% of the population, due to lack of access to effective treatment).
  • Young children and infants.
  • Pregnant women (especially primigravidae).
  • Elderly people.
  • Non-immune people (eg, travellers, foreign workers).

Outside endemic areas, returning travellers from these regions can develop malaria. Malaria is the most common imported tropical disease to the UK. Figures from Public Health England (PHE) show that In 2014, 1,586 cases of imported malaria were reported in the UK (1,475 in England, 76 in Scotland, 33 in Wales and 2 in Northern Ireland). This was 5.7% higher than reported in 2013 (1,501) and just 0.25% below the mean number of 1,590 cases between 2004 and 2013. Most cases in 2014 were caused by P. falciparum, as in previous years although there was a slight fall proportionally due to an increase in cases of P. vivax and P. ovale.[11] 

The risk of contracting malaria in travellers is proportional to the number of potentially infectious mosquito bites they receive. Therefore, risk factors for malaria in travellers include:[7] 

  • Travel to areas of high humidity and ambient temperature between 20-30°C (there is no malarial transmission <16°C or at altitudes >2000 m above sea level).
  • Travel at times of high seasonal rainfall.
  • Visits to rural locations (the risk of contracting malaria in African villages is eight times that in its urban areas).
  • Staying in cheap backpacker accommodation.
  • Being outdoors between dusk and dawn.
  • Longer durations of travel.

There are occasional cases of malaria (<2 per annum) reported in individuals who have never been in a malarious area or come into contact with infected blood (eg, blood transfusion or intravenous (IV) drug abuse). Such cases usually occur around airports and seaports - such 'airport malaria' is presumably caused by infected mosquitoes hitching a ride from endemic regions, in aircraft, ships, containers, luggage or buses. Always consider malaria a possibility in individuals working at or living close to such airports and ports.[12][13][14] 

Spread of drug resistance

Resistance to antimalarial drugs has spread rapidly over the past few decades - monitoring and surveillance have had to become more intensive to enable early detection of changing patterns of resistance so that national malaria treatment policies can be revised as necessary.

There are currently no effective alternatives to artemisinins for the treatment of resistant P. falciparum malaria. Artemisinin, derived from wormwood leaves, has been used in traditional Chinese medicine for centuries to treat malaria and other conditions but its use beyond China has only really happened in the last decade. Synthetic derivatives such as artemether and artesunate have greater bioavailability than artemisinin. Artemisinin-based combination therapies (ACTs) are life-saving in areas of high resistance. In order to preserve the efficacy of artemisinins, the World Health Organization (WHO) has called for a ban on the use of oral artemisinin monotherapies. Despite this, artemisinin-resistant cases have been reported. They are currently confined to Southeast Asia but should resistant parasites spread to Africa, this would represent a public health catastrophe. Genome-based research is currently being conducted to determine why artemisinins have been effective and what can be done to develop alternative therapies.[15] 

In view of the life cycle of the malaria parasite, symptoms may occur from six days of naturally acquired infection to many months later. Most patients with P. falciparum infection present in the first month or within the first six months of infection. P. vivax or P. ovale infections commonly present later than six months after exposure and sometimes after years.

There are no specific symptoms of malaria - so it is critical to consider the possibility of the diagnosis. Most missed malarial infections are wrongly diagnosed as nonspecific viral infections, influenza, gastroenteritis or hepatitis. Children, in particular, are more likely to present with nonspecific symptoms (fever, lethargy, malaise, somnolence) and to have gastrointestinal symptoms.

Where malaria is a possibility:

  • Take a careful exposure history (countries and areas of travel including stopovers and date of return, etc).
  • Determine what prophylaxis has been taken - drug(s), dose and adherence, date of cessation.
  • Pursue diagnostic tests urgently.

Symptoms

  • Fever, often recurring
  • Chills
  • Rigors
  • Headache
  • Cough
  • Myalgia
  • Gastrointestinal upset

Signs

  • Fever
  • Splenomegaly
  • Hepatomegaly
  • Jaundice
  • +/- abdominal tenderness

Signs of severe disease (usually P. falciparum)

  • Impaired consciousness.
  • Shortness of breath.
  • Bleeding.
  • Fits.
  • Hypovolaemia.
  • Hypoglycaemia.
  • Acute kidney injury.
  • Nephrotic syndrome.
  • Acute respiratory distress syndrome (during treatment).

As the initial presenting symptoms are nonspecific, there are many alternative diagnoses that could be considered; however, in any returning traveller, these should only be investigated once the possibility of malaria has been excluded, due to the serious consequences of a delay in diagnosis. Other travel-related infections that may present with similar symptoms include:

Prompt and accurate diagnosis of malaria is vital for effective case management:

  • To ensure appropriate drug treatment.
  • To prevent presumptive treatment of malaria (widespread in endemic areas).
  • To help reduce the mortality rate associated with the disease.

Diagnostic investigations include:

  • Thick and thin blood smears stained with Giemsa stain remain the 'gold standard'. Advantages include low cost and high sensitivity and specificity when used by well-trained staff. Where there is suspicion of malaria, a venous blood specimen in an EDTA tube should be sent to the laboratory in under an hour. If there is potential for delay, refer the patient to hospital for testing. Where the blood film is negative, at least two further films should be obtained over the subsequent 48 hours, before excluding the diagnosis. Be aware that an individual can have malaria despite a negative film. This is particularly the case in pregnancy where parasite biomass can be sequestered in the placenta - seek expert help early if concerned. See separate Malaria in Pregnancy article.
  • Rapid diagnostic tests (RDTs) which detect parasite antigens are available and, being dipstick-based investigations, are easier to use for staff without microscopy training. They have less waiting time and indirect costs but have been relatively more expensive. The World Health Organization (WHO) currently recommends either RDTs or microscopy confirmation before treatment.[17] 
  • Nucleic acid-based tests including polymerase chain reaction (PCR) have been developed but require more sophisticated training and equipment than RDTs and are more suited to epidemiological investigations.[17] 

All cases of malaria should be notified to public health authorities and a blood specimen sent to the Malaria Reference Laboratory for confirmation. Other investigations frequently performed include:

  • FBC - typically reveals thrombocytopenia and anaemia. Leukocytosis is rarely seen but is an indicator of a poor prognosis when present.
  • G6PD activity - prior to giving primaquine (see 'Treatment of non-falciparum malaria', below).
  • LFTs - often abnormal.
  • U&Es - may show lowered Na+ and increased creatinine.
  • Low blood glucose may be present in severe disease.

Ill patients may also require:

  • Blood gases.
  • Blood cultures.
  • Clotting studies.
  • Urine and stool culture.
  • CXR.
  • Lumbar puncture.

The management of malaria depends not only on the severity of the disease but also the strain of Plasmodium involved and the degree of resistance that it exhibits. All cases should be discussed with infectious disease specialists - the local infectious diseases unit will be able to give advice and initiate appropriate treatment in line with the current UK guidelines. Admission is usual for:

  • Severely unwell patients.
  • Patients with P. falciparum malaria.
  • Patients with mixed infections.
  • Patients in whom the strain cannot be identified.

See also separate Malaria in Pregnancy article.

Non-falciparum malaria

This is usually managed on an outpatient basis, unless the patient has other comorbidities. G6PD activity should be measured in P. vivax or P. ovale infections, as the primaquine (which is necessary to eliminate the dormant hypnozoites and prevent recurrence) can cause haemolysis in those with G6PD deficiency.

Treatment of non-falciparum malaria
Current UK guidelines recommend:

  • Chloroquine as the drug of choice for the treatment of all non-falciparum malaria - it is highly effective against P. malariae and P. ovale and most strains of P. vivax.
  • Where chloroquine fails, resistant P. vivax malaria can be treated with quinine, artemether with lumefantrine or atovaquone-proguanil as for uncomplicated falciparum malaria.
  • Prevention of relapse - primaquine is used to destroy liver stage parasites (unlicensed use):
    • For treatment of P. ovale 15 mg primaquine/day for 14 days.
    • Some strains of P. vivax require higher doses to prevent relapse, so 30 mg primaquine/day for 14 days.
    • Expert help should be enlisted in treating those with G6PD deficiency.

Falciparum malaria

Current guidelines suggest all patients with falciparum malaria should be admitted to hospital initially - even semi-immune patients may worsen quickly.[18] High-quality supportive management is important in patients with severe or complicated malaria: HDU management should be available with facilities for transfer to ICU if further deterioration occurs despite appropriate treatment.

Treatment for uncomplicated falciparum malaria
Current UK guidelines suggest as possible alternative regimens for adults:[19] 

  • Oral quinine sulfate 600 mg/8 hours for 5-7 days plus doxycycline 200 mg daily (or clindamycin 450 mg/8 hours for pregnant women) for seven days.
  • Atovaquone-proguanil (Malarone®): four standard tablets daily for three days.
  • Artemether with lumefantrine (Riamet®): if weight >35 kg, four tablets stat and then a further four tablets at 8, 24, 36, 48 and 60 hours.

NB: the WHO revised their treatment guidelines in 2010 and maintain these as current guidance.[20] These recommend that artemisinin-based combination therapies should be used first-line in preference to quinine. However, to date the UK has not yet changed its approach.

Treatment of severe or complicated falciparum malaria
Current UK guidelines suggest:[21] 

  • IV quinine dihydrochloride is the first-line antimalarial drug. A loading dose of 20 mg/kg (to a maximum of 1.4 g) over four hours, followed by 10 mg/kg (to a maximum of 700 mg) every eight hours for the first 48 hours or until the patient can swallow is usual to reach high therapeutic blood levels quickly, although alternative regimens exist. ECG monitoring is required.
  • Oral quinine sulfate 600 mg tds should be substituted once the patient is well enough to complete a 5- to 7-day course in total.
  • Artesunate regimen - for named adult patient use only, on expert advice. This is usually given as an IV injection, repeated at 12 and 24 hours and daily thereafter. Rectal formulations also exist but tend to be used in resource-poor settings where IV therapy is not possible. NB: IV artesunate has not been licensed in the UK but there is accumulating evidence that it offers a significant benefit over quinine where patients have very severe malaria or high parasite counts. A Cochrane review suggests that parenteral artesunate is the drug of choice for adults with severe malaria, in various parts of the world.[22] 
  • A second drug should always accompany these regimes. Current recommendations are for doxycycline 200 mg od (or clindamycin 450 mg tds for pregnant women) for a total of seven days from when the patient can swallow.

Complications are almost always associated with P. falciparum infection and include:

If left untreated, or where treatment is delayed, malaria may be fatal. However, the picture is improving. In the UK there were only three deaths in 2014, compared to seven the previous year, all in patients who acquired falciparum infection in Nigeria.[11] Globally, there were 438,000 deaths in the year 2015 but it has been calculated that since 2000, control and prevention measures have resulted in a 60% reduction in mortality rates.[2] Cerebral malaria has a mortality rate of about 20%.

See separate Malaria Prophylaxis article.

Use of effective chemoprophylaxis and insecticide-treated nets (ITNs) prevents about 90% of malaria.[7] Travellers should be encouraged to use a prophylactic regime appropriate to their travel itinerary but they should be aware that this is not a guarantee against infection.

Other behavioural modifications, such as avoiding outdoor activity after sunset, wearing long-sleeved shirts and trousers, using ITNs and insect repellant, must also be recognised as important.

Encouraging migrant travellers visiting family and friends to take prophylactic medication should be a priority - any immunity to malaria accrued by growing up in a malarious country is rapidly lost on emigration and second-generation family members will have no immunity, rendering them (and particularly children) vulnerable.[23]

The story of the human struggle to control malaria is not recent:

  • Malaria has its origins in the dramatic climate change in Africa 7,000-12,000 years ago (increase in temperature and humidity creating new water sources and the start of agriculture in the Middle East and North East Africa (forest-clearing and pools of water).
  • The occurrence and spread of malaria can be traced by the evolution of the G6PD, thalassaemia and sickle cell mutations, which in the carrier state give humans resistance to malaria. The appearance of one variant suggests the spread of malaria by the army of Alexander the Great.
  • Described first by the Chinese in the Nei Ching (the Canon of Medicine) in 2700 BC (or BCE - 'before common era', for non-Christians) and then, also described, the use of the qing hoa plant (annual or sweet wormwood) for fever in 340 AD (or CE - 'common era'). The active ingredient, artemisinin, was identified in 1971 and is in modern use as an antimalarial drug.
  • Malaria is Italian for 'bad air', as it was noted that shuttering up the houses and not going out in the evening reduced the risk from the gases of the swamp.
  • The bark of the Cinchona tree (containing quinine) in South America was found to be effective in treatment; legend describes taking its name from the countess of Chinchon, wife of a Peruvian viceroy who was cured of fever in 1658. It appeared in the British Pharmacopoeia in 1677 and later became known as 'Jesuit's powder' or 'Jesuit's bark' from those who first used it. The Dutch smuggled seeds from Bolivia and successfully grew this in their Indonesian colonies, obtaining a world monopoly on the supply, beating earlier attempts by themselves and the British using a different species which had poor yields.
  • Quinine was successfully synthesised in 1944.
  • Alphonse Laveran, a French military physician, discovered the protozoan parasite in 1880, whilst working in Algeria (he was later awarded the Nobel Prize for this in 1907).
  • The Italians, Grassi and Filetti, named P. vivax and P. malariae in 1890 and an American, Welch, named P. falciparum in 1897. Stephens named the last of the four, P. ovale, in 1922.
  • Ronald Ross, an officer in the Indian Medical Service, demonstrated the transmission of malaria by mosquito from bird to bird in 1897, earning the Nobel Prize in 1902.
  • Chloroquine was discovered in 1934 by the German Hans Andersag, although it was not recognised as an effective and safe antimalarial until 1946.
  • A German chemistry student synthesised DDT for his thesis in 1874, although its insecticidal properties were not recognised until 1939 by Müller, who won the Nobel Prize for Medicine in 1948.
  • It should not be forgotten that malaria was endemic in the marshes of Southern and Eastern England from the 16th to 19th centuries (species P. vivax and P. malariae) and briefly reappeared after both the First and Second World Wars.

The number of Nobel Prizes awarded to work on malaria is testimony to its global importance and human impact.

Further reading & references

  1. Dalrymple U, Mappin B, Gething PW; Malaria mapping: understanding the global endemicity of falciparum and vivax malaria. BMC Med. 2015 Jun 12;13:140. doi: 10.1186/s12916-015-0372-x.
  2. Malaria; World Health Organization, 2014 (updated 2016).
  3. Malaria; UNICEF
  4. Financing malaria control; World Health Organization, 2011
  5. Roll-Back Malaria Partnership; 2016
  6. Global Technical Strategy for Malaria 2016–2030; World Health Organization
  7. Guidelines for malaria prevention in travellers from the UK; Public Health England, 2015.
  8. Antinori S, Galimberti L, Milazzo L, et al; Plasmodium knowlesi: the emerging zoonotic malaria parasite. Acta Trop. 2013 Feb;125(2):191-201. doi: 10.1016/j.actatropica.2012.10.008. Epub 2012 Oct 23.
  9. 10 facts on malaria; World Health Organization, 2015
  10. Malaria; World Health Organization, 2016
  11. Malaria imported into the United Kingdom: 2014; Public Health England, 2015
  12. Gallien S, Taieb F, Hamane S, et al; Autochthonous falciparum malaria possibly transmitted by luggage-carried vector in Paris, France, February 2013. Euro Surveill. 2013 Oct 3;18(40). pii: 20600.
  13. Tatem AJ, Rogers DJ, Hay SI; Estimating the malaria risk of African mosquito movement by air travel. Malar J. 2006 Jul 14;5:57.
  14. Siala E, Gamara D, Kallel K, et al; Airport malaria: report of four cases in Tunisia. Malar J. 2015 Jan 28;14:42. doi: 10.1186/s12936-015-0566-x.
  15. Cravo P, Napolitano H, Culleton R; How genomics is contributing to the fight against artemisinin-resistant malaria parasites. Acta Trop. 2015 Aug;148:1-7. doi: 10.1016/j.actatropica.2015.04.007. Epub 2015 Apr 21.
  16. The PHE Malaria Reference Laboratory User Handbook, 2015; Public Health England
  17. Kobayashi T, Gamboa D, Ndiaye D, et al; Malaria Diagnosis Across the International Centers of Excellence for Malaria Research: Platforms, Performance, and Standardization. Am J Trop Med Hyg. 2015 Sep;93(3 Suppl):99-109. doi: 10.4269/ajtmh.15-0004. Epub 2015 Aug 10.
  18. Malaria: guidance, data and analysis; Public Health England
  19. Lalloo DG, Shingadia D, Pasvol G, et al; UK malaria treatment guidelines. J Infect. 2007 Feb;54(2):111-21. Epub 2007 Jan 9.
  20. Overview of malaria treatment; World Health Organization, 2015
  21. Lalloo D et al; UK malaria treatment guidelines; British Infection Society, 2007
  22. Sinclair D, Donegan S, Isba R, et al; Artesunate versus quinine for treating severe malaria. Cochrane Database Syst Rev. 2012 Jun 13;6:CD005967. doi: 10.1002/14651858.CD005967.pub4.
  23. Smith AD, Bradley DJ, Smith V, et al; Imported malaria and high risk groups: observational study using UK surveillance data 1987-2006. BMJ. 2008 Jul 3;337:a120. doi: 10.1136/bmj.a120.

Disclaimer: This article is for information only and should not be used for the diagnosis or treatment of medical conditions. EMIS has used all reasonable care in compiling the information but make no warranty as to its accuracy. Consult a doctor or other health care professional for diagnosis and treatment of medical conditions. For details see our conditions.

Original Author:
Dr Chloe Borton
Current Version:
Peer Reviewer:
Dr Adrian Bonsall
Document ID:
2415 (v27)
Last Checked:
22/02/2016
Next Review:
20/02/2021

Did you find this health information useful?

Yes No

Thank you for your feedback!

Subcribe to the Patient newsletter for healthcare and news updates.

We would love to hear your feedback!

 
 
Patient Access app - find out more Patient facebook page - Like our page